文献速递血栓与止血

周期性血小板减少症的高峰与低谷

The highs and lows of cyclic thrombocytopenia.
PubMed 文献 · Br J Haematol · 2023-12-11

周期性血小板减少症(CTP)以血小板周期性大幅波动为特征,常被误诊为免疫性血小板减少症而疗效不稳,也可发生于骨髓增殖性疾病接受羟基脲治疗时。本文综合历史、理论与临床发现,提出CTP保留血小板稳态调控的内在振荡因子,表现为血小板与血小板生成素的反向振荡及稳定周期,并探讨MPL、STAT3、DNMT3A等遗传变异及JAK2 V617F、BCR::ABL1在发病中的可能作用。

要点

  • CTP以血小板周期性大幅振荡为特征,多数有血小板减少背景,常被误诊为免疫性血小板减少症。
  • CTP保留稳态调控的内在振荡因子,表现为血小板与血小板生成素的反向振荡和稳定周期。
  • CTP患者存在 destabilizing 血小板稳态的致病因素,使外部扰动得以启动并维持过度振荡。

核心结论

  • CTP保留由血小板计数稳态调控所定义的内在振荡因子,表现为血小板与血小板生成素的反向振荡及稳定的振荡周期性。
  • CTP患者存在使血小板稳态系统失稳的致病因素,为外部扰动启动并维持过度血小板振荡创造条件。
  • 除体液与细胞介导的自身免疫外,新发现的胚系与体细胞遗传变异(如MPL、STAT3或DNMT3A)可能是血小板减少相关CTP的致病因素。
  • 驱动基础骨髓增殖性疾病的JAK2 V617F或BCR::ABL1易位也可能在羟基脲诱导的CTP中起致病作用,羟基脲治疗既可作为触发因素也可作为血小板振荡的致病因素。
  • 阐明CTP的致病全景为未来的靶向治疗提供了机会。

研究设计与样本

  • 本文为综述,评估历史、理论与临床发现以构建理解CTP病理生理学的框架。

主要发现

  • CTP以周期性血小板振荡且振幅较大为特征。
  • 多数CTP病例具有血小板减少背景,常被误诊为免疫性血小板减少症,治疗选择疗效不稳定。
  • CTP也可发生于骨髓增殖性疾病患者接受羟基脲治疗期间。
  • CTP的病因仍不确定。
  • CTP表现为血小板与血小板生成素的反向振荡及稳定的振荡周期性。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • CTP的病因仍不确定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cyclic thrombocytopenia (CTP) is characterized by periodic platelet oscillation with substantial amplitude. Most CTP cases have a thrombocytopenic background and are often misdiagnosed as immune thrombocytopenia with erratically effective treatment choices. CTP also occurs during hydroxyurea treatment in patients with myeloproliferative diseases. While the aetiology of CTP remains uncertain, here we evaluate historical, theoretical and clinical findings to provide a framework for understanding CTP pathophysiology. CTP retains the intrinsic oscillatory factors defined by the homeostatic regulation of platelet count, presenting as reciprocal platelet/thrombopoietin oscillations and stable oscillation periodicity. Moreover, CTP patients possess pathogenic factors destabilizing the platelet homeostatic system thereby creating opportunities for external perturbations to initiate and sustain the exaggerated platelet oscillations. Beyond humoral and cell-mediated autoimmunity, we propose recently uncovered germline and somatic genetic variants, such as those of MPL, STAT3 or DNMT3A, as pathogenic factors in thrombocytopenia-related CTP. Likewise, the JAK2 V617F or BCR::ABL1 translocation that drives underlying myeloproliferative diseases may also play a pathogenic role in hydroxyurea-induced CTP, where hydroxyurea treatment can serve as both a trigger and a pathogenic factor of platelet oscillation. Elucidating the pathogenic landscape of CTP provides an opportunity for targeted therapeutic approaches in the future.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Zhang H, Villar-Prados A, Bussel JB, et al. The highs and lows of cyclic thrombocytopenia. Br J Haematol. 2023. PMID: 38083878. doi:10.1111/bjh.19239

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。